{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-087372","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.915927+00:00","generated_at":"2026-06-26T15:15:23.886416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvalent reports $17.3M Q4 loss; IND cleared for ALK inhibitor NVL-655","bullets":["Q4 2021 net loss $17.3M; full-year net loss $46.3M, vs $14.6M in 2020.","Cash, equivalents, marketable securities $288.1M as of Dec 31, 2021; runway into 2024.","FDA cleared IND for NVL-655 (ALK-selective); ALKOVE-1 Phase 1/2 to start Q2 2022.","ARROS-1 trial of NVL-520 (ROS1) actively enrolling Phase 1 patients.","Discovery pipeline targeting ALK resistance and HER2 exon 20; 2 candidate nominations expected in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-087372","json":"https://secwatch.observer/filing/0001193125-22-087372.json","markdown":"https://secwatch.observer/filing/0001193125-22-087372.md","text":"https://secwatch.observer/filing/0001193125-22-087372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312522087372/0001193125-22-087372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312522087372/d307870d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T15:15:23.886416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}